Fixed dose drug combinations
Dr. Priyanka Saurabh
Health is the most important asset of any nation. Modern medical science has made unprecedented progress in the treatment of diseases, and a significant aspect of this progress is the combined use of various drugs. Many diseases require more than one drug for treatment. Keeping this need in mind, fixed-dose drug combinations (FDCs) were developed. FDCs are medicines that combine two or more active pharmaceutical ingredients in a specific ratio and are presented as a single drug. These can be in the form of tablets, capsules, syrups, or injections.
FDCs have become an important part of the medical world today. They are widely used in the treatment of high blood pressure, diabetes, tuberculosis, HIV infection, heart disease, asthma, and various infections. The World Health Organization also considers the use of FDCs useful in certain conditions. While they have many benefits, their uncontrolled and irrational use has also raised serious concerns. There has been a long-standing debate, particularly in India, regarding the regulation and quality of FDCs.
The basic purpose of FDCs is to simplify treatment. When a patient needs to take different medications multiple times a day, they often miss doses or don’t take them regularly. This impacts the success of treatment. If the same medications are available in a single pill, it becomes easier for the patient to take them. This is why FDCs are considered an effective tool to increase patient compliance.
The biggest advantage of FDCs is patient convenience. Containing multiple medications in a single tablet simplifies medication administration. This is particularly useful for older patients, children, and those on long-term treatment. Reducing the number of medications reduces the likelihood of patients discontinuing treatment. This advantage is particularly important in diseases like tuberculosis and HIV, where incomplete treatment can have serious consequences.
Another important benefit of FDCs is increased treatment effectiveness. In many diseases, combining different drugs produces better results. For example, the treatment of tuberculosis requires the combined use of multiple drugs because single-drug treatment can lead to bacterial resistance. Similarly, multi-drug therapy is part of the standard treatment for HIV infection. In such cases, FDCs simplify and make treatment more effective.
Another benefit of FDCs is controlling drug resistance. Antibiotic resistance has become a global health crisis. If a patient skips one of the necessary medications, the potential for pathogens to develop resistance increases. FDCs help mitigate this problem by giving all necessary medications simultaneously. This prevents the patient from skipping a single medication, making treatment more effective.
FDCs are also often economically beneficial. The production, packaging, transportation, and distribution costs of combined drugs can be lower than those of individual drugs. This reduces the financial burden on healthcare systems. The use of FDCs in large government health programs can also simplify drug management and supply systems.
FDCs are also useful for health administration. In national health programs, when medicines must be provided to large numbers of patients, distributing a single combined drug is more convenient than distributing individual drugs. This reduces storage requirements and makes it easier to ensure drug availability.
Despite these advantages, FDCs also pose several serious challenges. The most significant problem is the lack of dosage flexibility. Each patient’s needs are different. Often, a physician may want to increase or decrease the dosage of a particular drug, but this is impossible with FDCs because all the components are in fixed proportions. As a result, the patient must either change the entire drug or take a dosage that does not meet their needs.
Another major drawback of FDCs is that they make it difficult to identify side effects. If a patient experiences an allergic reaction or other adverse effect after taking a combined medication, it can be difficult to identify which component caused the problem. This can complicate treatment and compromise patient safety.
Another significant problem is unnecessary medication use. Sometimes, patients don’t need all the medications included in an FDC, yet they are still required to take the entire combination. This increases the risk of side effects and exposes patients to unnecessary additional medications. A fundamental principle of medical science is to give patients only the medication they need, but irrational FDCs can go against this principle.
The biggest concern regarding FDCs in India has been irrational combinations. For a long time, many drugs were available on the market for combinations that had no clear scientific basis. In some cases, the components of the drugs reduced rather than enhanced each other’s effects, while some combinations posed unnecessary risks to patients. This situation exposed the weaknesses of the drug regulatory system.
Irrational combinations of antibiotics have been a particular concern. Their improper use promotes resistance in bacteria. When antibiotics become ineffective, even common infections become difficult to treat. The World Health Organization has identified antibiotic resistance as one of the greatest threats to human health. Therefore, special caution is necessary in the use of antibiotic FDCs.
Challenges related to FDCs include the complexity of the regulatory system. Before any new FDC can be marketed, adequate scientific testing of its safety, efficacy, and quality must be conducted. Weak testing and evaluation processes can lead to unsafe or ineffective drugs reaching the market. In India, the central government has periodically banned several irrational FDCs, highlighting the severity of this problem.
India is one of the world’s largest drug producers, and the use of FDCs is widespread. Thousands of FDCs are available in the Indian pharmaceutical market. Many of these are scientifically justified and extremely beneficial to patients, while some combinations appear to have been developed solely for commercial gain. This is why experts have long stressed the need for a rational drug policy.
A rational FDC is one in which each ingredient has a clear role, all ingredients complement each other, their safety and effectiveness are scientifically proven, and their combined use is more beneficial than using them individually. A combination that does not meet these standards is not considered rational.
Looking ahead, India needs to adopt a balanced approach to FDCs. While recognizing the genuine benefits of these drugs, preventing their misuse and irrational use is crucial. This requires making the drug approval process more transparent and scientific. Physicians should be trained in rational drug use, and patients should be made aware that they should not use combination drugs without medical advice.
Pharmacovigilance, or drug side-effect monitoring, also needs to be strengthened. This will ensure that any FDC-related adverse effects are identified in a timely manner and necessary regulatory action can be taken. Effective national strategies must also be adopted to promote the judicious use of antibiotics.
Ultimately, it can be said that fixed-dose drug combinations are an important and useful tool of modern medical science. Their use, under appropriate circumstances, plays a crucial role in increasing patient compliance, simplifying treatment, reducing drug resistance, and improving the efficiency of healthcare services. However, their benefits can only be ensured if they are used based on scientific evidence, rational medical principles, and a robust regulatory system. Irrational FDCs not only pose risks to patients but can also pose serious challenges to public health. Therefore, it is essential that the development, acceptance, and use of FDCs in India be governed by the principles of scientificity, transparency, and patient welfare, so that this important achievement of medical science can become a means of real welfare for society.
(The author is a PhD in Political Science)
